{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T02:02:13Z","timestamp":1790301733626,"version":"4.1.0"},"reference-count":152,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,3,31]],"date-time":"2019-03-31T00:00:00Z","timestamp":1553990400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81870994"],"award-info":[{"award-number":["81870994"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Basic Research Program of China","doi-asserted-by":"publisher","award":["2016YFC1306000"],"award-info":[{"award-number":["2016YFC1306000"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine & Pharmacotherapy"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.biopha.2019.108843","type":"journal-article","created":{"date-parts":[[2019,5,2]],"date-time":"2019-05-02T18:28:43Z","timestamp":1556821723000},"page":"108843","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":61,"special_numbering":"C","title":["Progress of immunotherapy of anti-\u03b1-synuclein in Parkinson\u2019s disease"],"prefix":"10.1016","volume":"115","author":[{"given":"Zhipeng","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ge","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunli","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.biopha.2019.108843_bib0005","article-title":"Solvation-guided design of fluorescent probes for discrimination of amyloids","volume":"8","author":"Cao","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2019.108843_bib0010","article-title":"Interplay between alpha-synuclein amyloid formation and membrane structure","author":"O\u2019Leary","year":"2018","journal-title":"Biochim. Biophys. Acta Proteins Proteom."},{"key":"10.1016\/j.biopha.2019.108843_bib0015","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2018.00044","article-title":"Phospho-tau bar code: analysis of phosphoisotypes of tau and its application to tauopathy","volume":"12","author":"Kimura","year":"2018","journal-title":"Front. Neurosci."},{"issue":"5","key":"10.1016\/j.biopha.2019.108843_bib0020","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s004010050918","article-title":"Accumulation of alpha-synuclein\/NACP is a cytopathological feature common to Lewy body disease and multiple system atrophy","volume":"96","author":"Wakabayashi","year":"1998","journal-title":"Acta Neuropathol."},{"issue":"9996","key":"10.1016\/j.biopha.2019.108843_bib0025","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/S0140-6736(14)61393-3","article-title":"Parkinson\u2019s disease","volume":"386","author":"Kalia","year":"2015","journal-title":"Lancet"},{"issue":"7626","key":"10.1016\/j.biopha.2019.108843_bib0030","doi-asserted-by":"crossref","DOI":"10.1038\/538S17a","article-title":"Parkinson\u2019s disease: 4 big questions","volume":"538","author":"Deweerdt","year":"2016","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.biopha.2019.108843_bib0035","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/S1474-4422(15)00006-X","article-title":"Targeting alpha-synuclein for treatment of Parkinson\u2019s disease: mechanistic and therapeutic considerations","volume":"14","author":"Dehay","year":"2015","journal-title":"Lancet Neurol."},{"issue":"1","key":"10.1016\/j.biopha.2019.108843_bib0040","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/nrn3406","article-title":"The many faces of alpha-synuclein: from structure and toxicity to therapeutic target","volume":"14","author":"Lashuel","year":"2013","journal-title":"Nat. Rev. Neurosci."},{"issue":"7","key":"10.1016\/j.biopha.2019.108843_bib0045","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1097\/01.jnen.0000171652.40083.15","article-title":"Staging of sporadic Parkinson disease-related alpha-synuclein pathology: inter- and intra-rater reliability","volume":"64","author":"Muller","year":"2005","journal-title":"J. Neuropathol. Exp. Neurol."},{"issue":"8","key":"10.1016\/j.biopha.2019.108843_bib0050","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a009258","article-title":"Parkinson\u2019s disease and parkinsonism: neuropathology","volume":"2","author":"Dickson","year":"2012","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.biopha.2019.108843_bib0055","article-title":"Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs","author":"Charvin","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.biopha.2019.108843_bib0060","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s13311-013-0218-1","article-title":"Pathogenesis-targeted, disease-modifying therapies in Parkinson disease","volume":"11","author":"Aldakheel","year":"2014","journal-title":"Neurotherapeutics"},{"issue":"1","key":"10.1016\/j.biopha.2019.108843_bib0065","doi-asserted-by":"crossref","DOI":"10.1186\/s40478-018-0585-2","article-title":"Anti-tau conformational scFv MC1 antibody efficiently reduces pathological tau species in adult JNPL3 mice","volume":"6","author":"Vitale","year":"2018","journal-title":"Acta Neuropathol. Commun."},{"issue":"40","key":"10.1016\/j.biopha.2019.108843_bib0070","doi-asserted-by":"crossref","first-page":"15419","DOI":"10.1074\/jbc.R118.003999","article-title":"Are N- and C-terminally truncated Abeta species key pathological triggers in Alzheimer\u2019s disease?","volume":"293","author":"Dunys","year":"2018","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2019.108843_bib0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neuropharm.2018.09.001","article-title":"Blood-brain barrier integrity in a mouse model of Alzheimer\u2019s disease with or without acute 3D6 immunotherapy","volume":"143","author":"Gustafsson","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.biopha.2019.108843_bib0080","first-page":"1","article-title":"IL-17A and IL-23: plausible risk factors to induce age-associated inflammation in Alzheimer\u2019s disease","author":"Mohammadi","year":"2018","journal-title":"Immunol. Invest."},{"issue":"52","key":"10.1016\/j.biopha.2019.108843_bib0085","doi-asserted-by":"crossref","first-page":"43179","DOI":"10.1074\/jbc.M507624200","article-title":"Comparison of structure and dynamics of micelle-bound human alpha-synuclein and Parkinson disease variants","volume":"280","author":"Ulmer","year":"2005","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.biopha.2019.108843_bib0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/nm.4269","article-title":"\u03b1-synuclein toxicity in neurodegeneration: mechanism and therapeutic strategies","volume":"23","author":"Wong","year":"2017","journal-title":"Nat. Med."},{"key":"10.1016\/j.biopha.2019.108843_bib0095","doi-asserted-by":"crossref","first-page":"1025110","DOI":"10.1038\/ncomms10251","article-title":"Intracellular repair of oxidation-damaged alpha-synuclein fails to target C-terminal modification sites","volume":"7","author":"Binolfi","year":"2016","journal-title":"Nat. Commun."},{"issue":"9","key":"10.1016\/j.biopha.2019.108843_bib0100","doi-asserted-by":"crossref","first-page":"e7501810","DOI":"10.1371\/journal.pone.0075018","article-title":"Mechanistic insight into the relationship between N-terminal acetylation of alpha-synuclein and fibril formation rates by NMR and fluorescence","volume":"8","author":"Kang","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.biopha.2019.108843_bib0105","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0079-6123(10)83007-9","article-title":"Role of post-translational modifications in modulating the structure, function and toxicity of alpha-synuclein: implications for Parkinson\u2019s disease pathogenesis and \u2009therapies","volume":"183","author":"Oueslati","year":"2010","journal-title":"Prog. Brain Res."},{"issue":"12","key":"10.1016\/j.biopha.2019.108843_bib0110","doi-asserted-by":"crossref","first-page":"e11456610","DOI":"10.1371\/journal.pone.0114566","article-title":"Naturally occurring alpha-synuclein autoantibodies in Parkinson\u2019s disease: sources of (error) variance in biomarker assays","volume":"9","author":"Heinzel","year":"2014","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.biopha.2019.108843_bib0115","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/bpa.12370","article-title":"Alpha-synuclein as a biomarker for parkinson\u2019s disease","volume":"26","author":"Atik","year":"2016","journal-title":"Brain Pathol."},{"issue":"3","key":"10.1016\/j.biopha.2019.108843_bib0120","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s13311-013-0182-9","article-title":"alpha-Synuclein and mitochondria: partners in crime?","volume":"10","author":"Nakamura","year":"2013","journal-title":"Neurotherapeutics."},{"issue":"4","key":"10.1016\/j.biopha.2019.108843_bib0125","doi-asserted-by":"crossref","first-page":"e6214310","DOI":"10.1371\/journal.pone.0062143","article-title":"Alpha-synuclein induces lysosomal rupture and cathepsin dependent reactive oxygen species following endocytosis","volume":"8","author":"Freeman","year":"2013","journal-title":"PLoS One"},{"issue":"7-8","key":"10.1016\/j.biopha.2019.108843_bib0130","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1007\/s00018-008-7589-1","article-title":"Mitochondrial association of alpha-synuclein causes oxidative stress","volume":"65","author":"Parihar","year":"2008","journal-title":"Cell. Mol. Life Sci."},{"issue":"7","key":"10.1016\/j.biopha.2019.108843_bib0135","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1242\/jcs.161216","article-title":"Autophagosome dynamics in neurodegeneration at a glance","volume":"128","author":"Wong","year":"2015","journal-title":"J. Cell. Sci."},{"key":"10.1016\/j.biopha.2019.108843_bib0140","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.pneurobio.2013.10.004","article-title":"Autophagy and apoptosis dysfunction in neurodegenerative disorders","volume":"112","author":"Ghavami","year":"2014","journal-title":"Prog. Neurobiol."},{"issue":"6","key":"10.1016\/j.biopha.2019.108843_bib0145","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1083\/jcb.201003122","article-title":"Alpha-Synuclein impairs macroautophagy: implications for Parkinson\u2019s disease","volume":"190","author":"Winslow","year":"2010","journal-title":"J. Cell Biol."},{"issue":"2","key":"10.1016\/j.biopha.2019.108843_bib0150","first-page":"777","article-title":"Dopamine-modified alpha-synuclein blocks chaperone-mediated autophagy","volume":"118","author":"Martinez-Vicente","year":"2008","journal-title":"J. Clin. Invest."},{"issue":"21","key":"10.1016\/j.biopha.2019.108843_bib0155","doi-asserted-by":"crossref","first-page":"15194","DOI":"10.1074\/jbc.M113.457408","article-title":"Lewy body-like alpha-synuclein aggregates resist degradation and impair macroautophagy","volume":"288","author":"Tanik","year":"2013","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.biopha.2019.108843_bib0160","doi-asserted-by":"crossref","first-page":"429","DOI":"10.4161\/auto.7.4.14393","article-title":"The Parkinson disease protein alpha-synuclein inhibits autophagy","volume":"7","author":"Winslow","year":"2011","journal-title":"Autophagy"},{"issue":"4","key":"10.1016\/j.biopha.2019.108843_bib0165","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/S1474-4422(09)70062-6","article-title":"Neuroinflammation in Parkinson\u2019s disease: a target for neuroprotection?","volume":"8","author":"Hirsch","year":"2009","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.biopha.2019.108843_bib0170","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.parkreldis.2017.02.002","article-title":"Gut microbiota: implications in parkinson\u2019s disease","volume":"38","author":"Parashar","year":"2017","journal-title":"Parkinsonism Relat. Disord."},{"issue":"28","key":"10.1016\/j.biopha.2019.108843_bib0175","doi-asserted-by":"crossref","first-page":"9441","DOI":"10.1523\/JNEUROSCI.5314-13.2014","article-title":"Reducing C-terminal-truncated alpha-synuclein by immunotherapy attenuates neurodegeneration and propagation in Parkinson\u2019s disease-like \u2009models","volume":"34","author":"Games","year":"2014","journal-title":"J. Neurosci."},{"issue":"2","key":"10.1016\/j.biopha.2019.108843_bib0180","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/nm.4269","article-title":"Alpha-synuclein toxicity in neurodegeneration: mechanism and therapeutic strategies","volume":"23","author":"Wong","year":"2017","journal-title":"Nat. Med."},{"issue":"10","key":"10.1016\/j.biopha.2019.108843_bib0185","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.biopsych.2014.12.019","article-title":"Pathological interface between oligomeric alpha-synuclein and tau in synucleinopathies","volume":"78","author":"Sengupta","year":"2015","journal-title":"Biol. Psychiatry"},{"issue":"2","key":"10.1016\/j.biopha.2019.108843_bib0190","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1021\/bi501188a","article-title":"Purification of alpha-synuclein from human brain reveals an instability of endogenous multimers as the protein approaches purity","volume":"54","author":"Luth","year":"2015","journal-title":"Biochemistry"},{"key":"10.1016\/j.biopha.2019.108843_bib0195","doi-asserted-by":"crossref","first-page":"2452610","DOI":"10.1038\/srep24526","article-title":"Structural and functional properties of prefibrillar alpha-synuclein oligomers","volume":"6","author":"Pieri","year":"2016","journal-title":"Sci. Rep."},{"issue":"5","key":"10.1016\/j.biopha.2019.108843_bib0200","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/nrd3430","article-title":"Priorities in Parkinson\u2019s disease research","volume":"10","author":"Meissner","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.biopha.2019.108843_bib0205","doi-asserted-by":"crossref","first-page":"56710","DOI":"10.3389\/fneur.2017.00567","article-title":"Mutation analysis of consanguineous moroccan patients with parkinson\u2019s disease combining microarray and gene panel","volume":"8","author":"Bouhouche","year":"2017","journal-title":"Front. Neurol."},{"issue":"6","key":"10.1016\/j.biopha.2019.108843_bib0210","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.mcp.2016.11.001","article-title":"Genetics of Parkinson\u2019s disease","volume":"30","author":"Lill","year":"2016","journal-title":"Mol. Cell. Probes"},{"issue":"4","key":"10.1016\/j.biopha.2019.108843_bib0215","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1001\/archneur.65.4.514","article-title":"Patients homozygous and heterozygous for SNCA duplication in a family with parkinsonism and dementia","volume":"65","author":"Ikeuchi","year":"2008","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.biopha.2019.108843_bib0220","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.arr.2014.04.002","article-title":"Genetic variants and animal models in SNCA and Parkinson disease","volume":"15","author":"Deng","year":"2014","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.biopha.2019.108843_bib0225","first-page":"54646210","article-title":"Four copies of SNCA responsible for autosomal dominant parkinson\u2019s disease in two italian siblings","volume":"2015","author":"Ferese","year":"2015","journal-title":"Parkinsons Dis."},{"key":"10.1016\/j.biopha.2019.108843_bib0230","doi-asserted-by":"crossref","first-page":"e24110","DOI":"10.1038\/mtna.2015.14","article-title":"Normalization of overexpressed alpha-synuclein causing parkinson\u2019s disease by a moderate gene silencing with RNA interference","volume":"4","author":"Takahashi","year":"2015","journal-title":"Mol. Ther. Nucleic Acids"},{"issue":"3","key":"10.1016\/j.biopha.2019.108843_bib0235","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0304-3940(02)01258-2","article-title":"Phosphorylation of alpha-synuclein characteristic of synucleinopathy lesions is recapitulated in alpha-synuclein transgenic Drosophila","volume":"336","author":"Takahashi","year":"2003","journal-title":"Neurosci. Lett."},{"issue":"9","key":"10.1016\/j.biopha.2019.108843_bib0240","doi-asserted-by":"crossref","first-page":"3184","DOI":"10.1523\/JNEUROSCI.5922-09.2010","article-title":"Phosphorylation at S87 is enhanced in synucleinopathies, inhibits alpha-synuclein oligomerization, and influences synuclein-membrane interactions","volume":"30","author":"Paleologou","year":"2010","journal-title":"J. Neurosci."},{"issue":"2","key":"10.1016\/j.biopha.2019.108843_bib0245","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1515\/revneuro-2012-0071","article-title":"The role of Ser129 phosphorylation of alpha-synuclein in neurodegeneration of Parkinson\u2019s disease: a review of in vivo \u2009models","volume":"24","author":"Sato","year":"2013","journal-title":"Rev. Neurosci."},{"issue":"5","key":"10.1016\/j.biopha.2019.108843_bib0250","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1097\/NEN.0b013e3186fc995","article-title":"Specificity and regulation of casein kinase-mediated phosphorylation of alpha-synuclein","volume":"67","author":"Waxman","year":"2008","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.biopha.2019.108843_bib0255","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0079-6123(10)83007-9","article-title":"Role of post-translational modifications in modulating the structure, function and toxicity of alpha-synuclein: implications for Parkinson\u2019s disease pathogenesis and therapies","volume":"183","author":"Oueslati","year":"2010","journal-title":"Prog. Brain Res."},{"issue":"46","key":"10.1016\/j.biopha.2019.108843_bib0260","doi-asserted-by":"crossref","first-page":"16884","DOI":"10.1523\/JNEUROSCI.3967-11.2011","article-title":"Authentically phosphorylated alpha-synuclein at Ser129 accelerates neurodegeneration in a rat model of familial Parkinson\u2019s disease","volume":"31","author":"Sato","year":"2011","journal-title":"J. Neurosci."},{"issue":"9","key":"10.1016\/j.biopha.2019.108843_bib0265","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1016\/j.neurobiolaging.2015.06.004","article-title":"Increased oligomerization and phosphorylation of alpha-synuclein are associated with decreased activity of glucocerebrosidase and protein phosphatase 2A in aging monkey brains","volume":"36","author":"Liu","year":"2015","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.biopha.2019.108843_bib0270","doi-asserted-by":"crossref","first-page":"17310","DOI":"10.3389\/fnagi.2018.00173","article-title":"Leucine carboxyl methyltransferase downregulation and protein phosphatase methylesterase upregulation contribute toward the inhibition of protein phosphatase 2A by alpha-synuclein","volume":"10","author":"Tian","year":"2018","journal-title":"Front. Aging Neurosci."},{"issue":"Pt 6","key":"10.1016\/j.biopha.2019.108843_bib0275","first-page":"1416","article-title":"A GEF-to-phospholipase molecular switch caused by phosphatidic acid, Rac and JAK tyrosine kinase that explains leukocyte cell migration","volume":"126","author":"Mahankali","year":"2013","journal-title":"J. Cell. Sci."},{"issue":"2","key":"10.1016\/j.biopha.2019.108843_bib0280","doi-asserted-by":"crossref","first-page":"97","DOI":"10.5607\/en.2017.26.2.97","article-title":"Optogenetic rescue of locomotor dysfunction and dopaminergic degeneration caused by Alpha-Synuclein and EKO genes","volume":"26","author":"Qi","year":"2017","journal-title":"Exp. Neurobiol."},{"issue":"6","key":"10.1016\/j.biopha.2019.108843_bib0285","doi-asserted-by":"crossref","first-page":"e9890610","DOI":"10.1371\/journal.pone.0098906","article-title":"Modelling Ser129 phosphorylation inhibits membrane binding of pore-forming alpha-synuclein oligomers","volume":"9","author":"Nubling","year":"2014","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.biopha.2019.108843_bib0290","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1515\/revneuro-2012-0071","article-title":"The role of Ser129 phosphorylation of alpha-synuclein in neurodegeneration of Parkinson\u2019s disease: a review of in vivo models","volume":"24","author":"Sato","year":"2013","journal-title":"Rev. Neurosci."},{"issue":"24","key":"10.1016\/j.biopha.2019.108843_bib0295","doi-asserted-by":"crossref","first-page":"16895","DOI":"10.1074\/jbc.M800747200","article-title":"Phosphorylation at Ser-129 but not the phosphomimics S129E\/D inhibits the fibrillation of alpha-synuclein","volume":"283","author":"Paleologou","year":"2008","journal-title":"J. Biol. Chem."},{"issue":"6776","key":"10.1016\/j.biopha.2019.108843_bib0300","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1038\/35006074","article-title":"A Drosophila model of parkinson\u2019s disease","volume":"404","author":"Feany","year":"2000","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.biopha.2019.108843_bib0305","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1021\/acschembio.6b00539","article-title":"Semisynthetic and in vitro phosphorylation of Alpha-Synuclein at Y39 promotes functional partly helical membrane-bound states resembling those induced by PD mutations","volume":"11","author":"Dikiy","year":"2016","journal-title":"ACS Chem. Biol."},{"issue":"May 9","key":"10.1016\/j.biopha.2019.108843_bib0310","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1089\/ars.2013.5250","article-title":"the evaluation of nitrosative stress through selective increase of 3-nitrotyrosine proteins other than nitroalbumin and dominant tyrosine-125\/136 nitrosylation of serum alpha-synuclein serve for diagnosis of sporadic Parkinson\u2019s disease?","volume":"19","author":"Fernandez","year":"2013","journal-title":"Antioxid. Redox Signal."},{"issue":"8","key":"10.1016\/j.biopha.2019.108843_bib0315","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1038\/nsmb.3433","article-title":"Asparagine endopeptidase cleaves \u03b1-synuclein and mediates pathologic activities in Parkinson\u2019s disease","volume":"24","author":"Zhang","year":"2017","journal-title":"Nat. Struct. Mol. Biol."},{"issue":"28","key":"10.1016\/j.biopha.2019.108843_bib0320","doi-asserted-by":"crossref","first-page":"9441","DOI":"10.1523\/JNEUROSCI.5314-13.2014","article-title":"Reducing C-Terminal-Truncated alpha-synuclein by immunotherapy attenuates neurodegeneration and propagation in parkinson\u2019s disease-like models","volume":"34","author":"Games","year":"2014","journal-title":"J. Neurosci."},{"issue":"21","key":"10.1016\/j.biopha.2019.108843_bib0325","doi-asserted-by":"crossref","first-page":"7818","DOI":"10.1021\/bi047846q","article-title":"Cleavage of alpha-synuclein by calpain: potential role in degradation of fibrillized and nitrated species of alpha-synuclein","volume":"44","author":"Mishizen-Eberz","year":"2005","journal-title":"Biochemistry"},{"issue":"6","key":"10.1016\/j.biopha.2019.108843_bib0330","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1073\/pnas.0406976102","article-title":"Aggregation promoting C-terminal truncation of alpha-synuclein is a normal cellular process and is enhanced by the familial Parkinson\u2019s disease-linked mutations","volume":"102","author":"Li","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"5","key":"10.1016\/j.biopha.2019.108843_bib0335","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.2353\/ajpath.2007.061232","article-title":"Calpain-cleavage of alpha-synuclein: connecting proteolytic processing to disease-linked aggregation","volume":"170","author":"Dufty","year":"2007","journal-title":"Am. J. Pathol."},{"issue":"1","key":"10.1016\/j.biopha.2019.108843_bib0340","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s10863-009-9258-y","article-title":"Accelerated formation of alpha-synuclein oligomers by concerted action of the 20S proteasome and familial Parkinson mutations","volume":"42","author":"Lewis","year":"2010","journal-title":"J. Bioenerg. Biomembr."},{"issue":"28","key":"10.1016\/j.biopha.2019.108843_bib0345","doi-asserted-by":"crossref","first-page":"9441","DOI":"10.1523\/JNEUROSCI.5314-13.2014","article-title":"Reducing C-terminal-truncated alpha-synuclein by immunotherapy attenuates neurodegeneration and propagation in Parkinson\u2019s disease-like models","volume":"34","author":"Games","year":"2014","journal-title":"J. Neurosci."},{"issue":"36","key":"10.1016\/j.biopha.2019.108843_bib0350","doi-asserted-by":"crossref","first-page":"9678","DOI":"10.1021\/bi800699v","article-title":"Cathepsin D is the main lysosomal enzyme involved in the degradation of alpha-synuclein and generation of its carboxy-terminally truncated species","volume":"47","author":"Sevlever","year":"2008","journal-title":"Biochemistry"},{"issue":"1","key":"10.1016\/j.biopha.2019.108843_bib0355","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.expneurol.2008.10.010","article-title":"Increased alpha-synuclein aggregation following limited cleavage by certain matrix metalloproteinases","volume":"215","author":"Levin","year":"2009","journal-title":"Exp. Neurol."},{"issue":"1","key":"10.1016\/j.biopha.2019.108843_bib0360","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.neuron.2011.08.033","article-title":"Exogenous alpha-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death","volume":"72","author":"Volpicelli-Daley","year":"2011","journal-title":"Neuron"},{"issue":"9","key":"10.1016\/j.biopha.2019.108843_bib0365","doi-asserted-by":"crossref","first-page":"e313510","DOI":"10.1371\/journal.pone.0003135","article-title":"Mechanisms of hybrid oligomer formation in the pathogenesis of combined Alzheimer\u2019s and Parkinson\u2019s diseases","volume":"3","author":"Tsigelny","year":"2008","journal-title":"PLoS One"},{"issue":"6109","key":"10.1016\/j.biopha.2019.108843_bib0370","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1126\/science.1227157","article-title":"Pathological alpha-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice","volume":"338","author":"Luk","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.biopha.2019.108843_bib0375","article-title":"Addition of exogenous \u03b1-Synuclein Pre-formed fibrils to Primary Neuronal Cultures to seed recruitment of endogenous \u03b1-Synuclein to Lewy body and Lewy Neurite-like aggregates","author":"Laura","year":"2014","journal-title":"HHS Public Access"},{"key":"10.1016\/j.biopha.2019.108843_bib0380","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1146\/annurev.neuro.26.010302.081142","article-title":"Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders","volume":"26","author":"Caughey","year":"2003","journal-title":"Annu. Rev. Neurosci."},{"issue":"47","key":"10.1016\/j.biopha.2019.108843_bib0385","doi-asserted-by":"crossref","first-page":"20051","DOI":"10.1073\/pnas.0908005106","article-title":"Exogenous alpha-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells","volume":"106","author":"Luk","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"7556","key":"10.1016\/j.biopha.2019.108843_bib0390","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/nature14547","article-title":"Alpha-Synuclein strains cause distinct synucleinopathies after local and systemic administration","volume":"522","author":"Peelaerts","year":"2015","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.biopha.2019.108843_bib0395","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1111\/j.1742-4658.2012.08489.x","article-title":"Role of alpha-synuclein penetration into the membrane in the mechanisms of oligomer pore formation","volume":"279","author":"Tsigelny","year":"2012","journal-title":"FEBS J."},{"key":"10.1016\/j.biopha.2019.108843_bib0400","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.nbd.2017.12.004","article-title":"Toxic properties of microsome-associated alpha-synuclein species in mouse primary neurons","volume":"111","author":"Colla","year":"2018","journal-title":"Neurobiol. Dis."},{"issue":"10","key":"10.1016\/j.biopha.2019.108843_bib0405","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1038\/s41593-018-0238-6","article-title":"Propagation and spread of pathogenic protein assemblies in neurodegenerative diseases","volume":"21","author":"Jucker","year":"2018","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.biopha.2019.108843_bib0410","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.gde.2017.03.011","article-title":"Prion-like transmission of pathogenic protein aggregates in genetic models of neurodegenerative disease","volume":"44","author":"Pearce","year":"2017","journal-title":"Curr. Opin. Genet. Dev."},{"issue":"1","key":"10.1016\/j.biopha.2019.108843_bib0415","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1186\/s40478-017-0413-0","article-title":"Propagation of pathological alpha-synuclein in marmoset brain","volume":"5","author":"Shimozawa","year":"2017","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.biopha.2019.108843_bib0420","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.nbd.2014.07.002","article-title":"Spreading of alpha-synuclein in the face of axonal transport deficits in Parkinson\u2019s disease: a speculative synthesis","volume":"77","author":"Lamberts","year":"2015","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.biopha.2019.108843_bib0425","doi-asserted-by":"crossref","DOI":"10.1007\/s12264-017-0179-1","article-title":"Age-dependent alpha-synuclein accumulation and phosphorylation in the enteric nervous system in a transgenic mouse model of parkinson\u2019s disease","author":"Zhong","year":"2017","journal-title":"Neurosci. Bull."},{"key":"10.1016\/j.biopha.2019.108843_bib0430","article-title":"The transport mechanism of extracellular vesicles at the blood-brain barrier","author":"Matsumoto","year":"2017","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.biopha.2019.108843_bib0435","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.omtn.2018.01.007","article-title":"Supplemental treatment for huntington\u2019s disease with miR-132 that is deficient in Huntington\u2019s disease brain","volume":"11","author":"Fukuoka","year":"2018","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.biopha.2019.108843_bib0440","doi-asserted-by":"crossref","first-page":"257510","DOI":"10.1038\/ncomms3575","article-title":"Structural and functional characterization of two alpha-synuclein strains","volume":"4","author":"Bousset","year":"2013","journal-title":"Nat. Commun."},{"issue":"7660","key":"10.1016\/j.biopha.2019.108843_bib0445","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/nature22815","article-title":"T cells from patients with Parkinson\u2019s disease recognize \u03b1-synuclein peptides","volume":"546","author":"Sulzer","year":"2017","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.biopha.2019.108843_bib0450","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1016\/j.celrep.2014.05.033","article-title":"Alpha-synuclein immunotherapy blocks uptake and templated propagation of misfolded alpha-synuclein and neurodegeneration","volume":"7","author":"Tran","year":"2014","journal-title":"Cell Rep."},{"key":"10.1016\/j.biopha.2019.108843_bib0455","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.expneurol.2017.10.003","article-title":"Therapeutic approaches to target alpha-synuclein pathology","volume":"298","author":"Brundin","year":"2017","journal-title":"Exp. Neurol."},{"issue":"2","key":"10.1016\/j.biopha.2019.108843_bib0460","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1002\/mds.26377","article-title":"Active immunization therapies for Parkinson\u2019s disease and multiple system atrophy","volume":"31","author":"Schneeberger","year":"2016","journal-title":"Mov. Disord."},{"key":"10.1016\/j.biopha.2019.108843_bib0465","doi-asserted-by":"crossref","DOI":"10.1021\/acschemneuro.7b00063","article-title":"Immunochemical detection of alpha-synuclein autoantibodies in parkinson\u2019s disease: correlation between plasma and cerebrospinal fluid levels","author":"Horvath","year":"2017","journal-title":"ACS Chem. Neurosci."},{"issue":"2","key":"10.1016\/j.biopha.2019.108843_bib0470","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1080\/14760584.2016.1229602","article-title":"Immunotherapies for neurodegenerative diseases: current status and potential of plant-made biopharmaceuticals","volume":"16","author":"Arevalo-Villalobos","year":"2017","journal-title":"Expert Rev. Vaccines"},{"issue":"6","key":"10.1016\/j.biopha.2019.108843_bib0475","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.neuron.2005.05.010","article-title":"Effects of alpha-synuclein immunization in a mouse model of Parkinson\u2019s disease","volume":"46","author":"Masliah","year":"2005","journal-title":"Neuron."},{"key":"10.1016\/j.biopha.2019.108843_bib0480","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.neulet.2013.12.028","article-title":"Immunogenicity of epitope vaccines targeting different B cell antigenic determinants of human alpha-synuclein: feasibility study","volume":"560","author":"Ghochikyan","year":"2014","journal-title":"Neurosci. Lett."},{"issue":"7356","key":"10.1016\/j.biopha.2019.108843_bib0485","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1038\/nature10317","article-title":"Molecular chaperones in protein folding and proteostasis","volume":"475","author":"Hartl","year":"2011","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.biopha.2019.108843_bib0490","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1007\/s00425-017-2675-y","article-title":"LTB-Syn: a recombinant immunogen for the development of plant-made vaccines against synucleinopathies","volume":"245","author":"Arevalo-Villalobos","year":"2017","journal-title":"Planta"},{"key":"10.1016\/j.biopha.2019.108843_bib0495","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.neurobiolaging.2017.08.006","article-title":"MultiTEP platform-based DNA vaccines for alpha-synucleinopathies: preclinical evaluation of immunogenicity and therapeutic potency","volume":"59","author":"Davtyan","year":"2017","journal-title":"Neurobiol. Aging"},{"issue":"4","key":"10.1016\/j.biopha.2019.108843_bib0500","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1080\/21645515.2015.1012033","article-title":"Evaluation of an alpha synuclein sensitized dendritic cell based vaccine in a transgenic mouse model of Parkinson disease","volume":"11","author":"Ugen","year":"2015","journal-title":"Hum. Vaccin. Immunother."},{"issue":"11","key":"10.1016\/j.biopha.2019.108843_bib0505","doi-asserted-by":"crossref","first-page":"948","DOI":"10.4161\/hv.6.11.13217","article-title":"AFFITOME(R) technology in neurodegenerative diseases: the doubling advantage","volume":"6","author":"Schneeberger","year":"2010","journal-title":"Hum. Vaccin."},{"issue":"2","key":"10.1016\/j.biopha.2019.108843_bib0510","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1172\/JCI82670","article-title":"Activating transcription factor 6 derepression mediates neuroprotection in Huntington disease","volume":"126","author":"Naranjo","year":"2016","journal-title":"J. Clin. Invest."},{"issue":"11","key":"10.1016\/j.biopha.2019.108843_bib0515","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.5692\/clinicalneurol.51.1160","article-title":"[Antibody therapy for Alzheimer\u2019s disease]","volume":"51","author":"Tabira","year":"2011","journal-title":"Rinsho Shinkeigaku"},{"key":"10.1016\/j.biopha.2019.108843_bib0520","series-title":"The Antibody Aducanumab Reduces A\u03b2 Plaques in Alzheimer\u2019s Disease[M]","first-page":"50","author":"Sevigny","year":"2016"},{"key":"10.1016\/j.biopha.2019.108843_bib0525","doi-asserted-by":"crossref","DOI":"10.1016\/j.expneurol.2017.10.003","article-title":"Therapeutic approaches to target alpha-synuclein pathology","author":"Brundin","year":"2017","journal-title":"Exp. Neurol."},{"issue":"3","key":"10.1016\/j.biopha.2019.108843_bib0530","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/nrneurol.2017.188","article-title":"Blood-brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders","volume":"14","author":"Sweeney","year":"2018","journal-title":"Nat. Rev. Neurol."},{"issue":"2","key":"10.1016\/j.biopha.2019.108843_bib0535","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.jmb.2010.07.001","article-title":"Structure and properties of a complex of alpha-synuclein and a single-domain camelid antibody","volume":"402","author":"De Genst","year":"2010","journal-title":"J. Mol. Biol."},{"issue":"14","key":"10.1016\/j.biopha.2019.108843_bib0540","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1016\/j.jmb.2013.01.040","article-title":"Nanobodies raised against monomeric alpha-synuclein distinguish between fibrils at different maturation stages","volume":"425","author":"Guilliams","year":"2013","journal-title":"J. Mol. Biol."},{"issue":"1","key":"10.1016\/j.biopha.2019.108843_bib0545","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.celrep.2017.12.019","article-title":"Brain shuttle antibody for alzheimer\u2019s disease with attenuated peripheral effector function due to an inverted binding mode","volume":"22","author":"Weber","year":"2018","journal-title":"Cell Rep."},{"issue":"2","key":"10.1016\/j.biopha.2019.108843_bib0550","doi-asserted-by":"crossref","first-page":"308","DOI":"10.7150\/thno.17155","article-title":"Bivalent brain shuttle increases antibody uptake by monovalent binding to the transferrin receptor","volume":"7","author":"Hultqvist","year":"2017","journal-title":"Theranostics"},{"issue":"5","key":"10.1016\/j.biopha.2019.108843_bib0555","doi-asserted-by":"crossref","first-page":"779","DOI":"10.2174\/1570159X01666160930121647","article-title":"Recombinant antibody fragments for neurodegenerative diseases","volume":"15","author":"Manoutcharian","year":"2017","journal-title":"Curr. Neuropharmacol."},{"issue":"7","key":"10.1016\/j.biopha.2019.108843_bib0560","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.bbadis.2008.09.001","article-title":"Intrabody and Parkinson\u2019s disease","volume":"1792","author":"Zhou","year":"2009","journal-title":"Biochim. Biophys. Acta"},{"issue":"6","key":"10.1016\/j.biopha.2019.108843_bib0565","doi-asserted-by":"crossref","first-page":"686","DOI":"10.4161\/mabs.21696","article-title":"Fusion to a highly charged proteasomal retargeting sequence increases soluble cytoplasmic expression and efficacy of diverse anti-synuclein intrabodies","volume":"4","author":"Joshi","year":"2012","journal-title":"MAbs"},{"issue":"6","key":"10.1016\/j.biopha.2019.108843_bib0570","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.ymthe.2004.08.019","article-title":"A human single-chain Fv intrabody blocks aberrant cellular effects of overexpressed alpha-synuclein","volume":"10","author":"Zhou","year":"2004","journal-title":"Mol. Ther."},{"issue":"9","key":"10.1016\/j.biopha.2019.108843_bib0575","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/nrn1199","article-title":"The role of alpha-synuclein in Parkinson\u2019s disease: insights from animal models","volume":"4","author":"Maries","year":"2003","journal-title":"Nat. Rev. Neurosci."},{"issue":"17","key":"10.1016\/j.biopha.2019.108843_bib0580","doi-asserted-by":"crossref","first-page":"11048","DOI":"10.1074\/jbc.M806559200","article-title":"Detecting morphologically distinct oligomeric forms of alpha-synuclein","volume":"284","author":"Emadi","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2019.108843_bib0585","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.nbd.2017.05.002","article-title":"Differential effects of immunotherapy with antibodies targeting? -Synuclein oligomers and fibrils in a transgenic model of synucleinopathy","volume":"104","author":"El-Agnaf","year":"2017","journal-title":"Neurobiol. Dis."},{"issue":"1","key":"10.1016\/j.biopha.2019.108843_bib0590","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s10571-016-0352-5","article-title":"Cellular uptake of alpha-synuclein oligomer-selective antibodies is enhanced by the extracellular presence of alpha-synuclein and mediated via fcgamma receptors","volume":"37","author":"Gustafsson","year":"2017","journal-title":"Cell. Mol. Neurobiol."},{"issue":"12","key":"10.1016\/j.biopha.2019.108843_bib0595","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1038\/nbt1262","article-title":"An essential role for Akt1 in dendritic cell function and tumor immunotherapy","volume":"24","author":"Park","year":"2006","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.biopha.2019.108843_bib0600","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.nbd.2018.10.016","article-title":"Development of an aggregate-selective, human-derived alpha-synuclein antibody BIIB054 that ameliorates disease phenotypes in Parkinson\u2019s disease models","volume":"124","author":"Weihofen","year":"2018","journal-title":"Neurobiol. Dis."},{"issue":"1","key":"10.1016\/j.biopha.2019.108843_bib0605","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1186\/s40478-016-0410-8","article-title":"Anti-alpha-synuclein immunotherapy reduces alpha-synuclein propagation in the axon and degeneration in a combined viral vector and transgenic model of synucleinopathy","volume":"5","author":"Spencer","year":"2017","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.biopha.2019.108843_bib0610","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.bpc.2016.11.002","article-title":"Antibodies against the C-terminus of alpha-synuclein modulate its fibrillation","volume":"220","author":"Sahin","year":"2017","journal-title":"Biophys. Chem."},{"key":"10.1016\/j.biopha.2019.108843_bib0615","doi-asserted-by":"crossref","DOI":"10.1001\/jamaneurol.2018.1487","article-title":"Safety and tolerability of multiple ascending doses of PRX002\/RG7935, an anti-alpha-Synuclein monoclonal antibody, in patients with parkinson disease: a randomized clinical trial","author":"Jankovic","year":"2018","journal-title":"JAMA Neurol."},{"issue":"2","key":"10.1016\/j.biopha.2019.108843_bib0620","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/mds.26878","article-title":"First-in-human assessment of PRX002, an anti-alpha-synuclein monoclonal antibody, in healthy volunteers","volume":"32","author":"Schenk","year":"2017","journal-title":"Mov. Disord."},{"issue":"39","key":"10.1016\/j.biopha.2019.108843_bib0625","doi-asserted-by":"crossref","first-page":"13454","DOI":"10.1523\/JNEUROSCI.1292-12.2012","article-title":"Antibody-aided clearance of extracellular alpha-synuclein prevents cell-to-cell aggregate transmission","volume":"32","author":"Bae","year":"2012","journal-title":"J. Neurosci."},{"issue":"1","key":"10.1016\/j.biopha.2019.108843_bib0630","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.jmb.2007.11.096","article-title":"An scFv intrabody against the nonamyloid component of alpha-synuclein reduces intracellular aggregation and toxicity","volume":"377","author":"Lynch","year":"2008","journal-title":"J. Mol. Biol."},{"issue":"11","key":"10.1016\/j.biopha.2019.108843_bib0635","doi-asserted-by":"crossref","first-page":"e16596410","DOI":"10.1371\/journal.pone.0165964","article-title":"Bifunctional anti-non-Amyloid component alpha-synuclein nanobodies are protective in situ","volume":"11","author":"Butler","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.biopha.2019.108843_bib0640","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.1038\/s41531-018-0062-4","article-title":"Proteasome-targeted nanobodies alleviate pathology and functional decline in an alpha-synuclein-based Parkinson\u2019s disease model","volume":"4","author":"Chatterjee","year":"2018","journal-title":"NPJ Parkinsons Dis."},{"issue":"2","key":"10.1016\/j.biopha.2019.108843_bib0645","doi-asserted-by":"crossref","first-page":"e11684110","DOI":"10.1371\/journal.pone.0116841","article-title":"Anti-human alpha-synuclein N-terminal peptide antibody protects against dopaminergic cell death and ameliorates behavioral deficits in an AAV-alpha-synuclein rat model of Parkinson\u2019s disease","volume":"10","author":"Shahaduzzaman","year":"2015","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.biopha.2019.108843_bib0650","doi-asserted-by":"crossref","first-page":"8010","DOI":"10.1186\/s40478-016-0357-9","article-title":"Novel antibodies to phosphorylated alpha-synuclein serine 129 and NFL serine 473 demonstrate the close molecular homology of these epitopes","volume":"4","author":"Rutherford","year":"2016","journal-title":"Acta Neuropathol. Commun."},{"issue":"1","key":"10.1016\/j.biopha.2019.108843_bib0655","doi-asserted-by":"crossref","first-page":"4810","DOI":"10.1186\/s40478-017-0452-6","article-title":"Mechanisms underlying extensive Ser129-phosphorylation in alpha-synuclein aggregates","volume":"5","author":"Arawaka","year":"2017","journal-title":"Acta Neuropathol. Commun."},{"issue":"12","key":"10.1016\/j.biopha.2019.108843_bib0660","doi-asserted-by":"crossref","first-page":"4127","DOI":"10.1096\/fj.10-179192","article-title":"Phosphorylated alpha-synuclein can be detected in blood plasma and is potentially a useful biomarker for Parkinson\u2019s disease","volume":"25","author":"Foulds","year":"2011","journal-title":"FASEB J."},{"issue":"121","key":"10.1016\/j.biopha.2019.108843_bib0665","doi-asserted-by":"crossref","first-page":"120r","DOI":"10.1126\/scitranslmed.3002566","article-title":"Phosphorylated alpha-synuclein in Parkinson\u2019s disease","volume":"4","author":"Wang","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.biopha.2019.108843_bib0670","doi-asserted-by":"crossref","DOI":"10.1021\/acs.molpharmaceut.8b00594","article-title":"Brain penetrating bifunctional erythropoietin-transferrin receptor antibody fusion protein for alzheimer\u2019s disease","author":"Chang","year":"2018","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.biopha.2019.108843_bib0675","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neuropharm.2018.09.001","article-title":"Blood-brain barrier integrity in a mouse model of Alzheimer\u2019s disease with or without acute 3D6 immunotherapy","volume":"143","author":"Gustafsson","year":"2018","journal-title":"Neuropharmacology"},{"issue":"7560","key":"10.1016\/j.biopha.2019.108843_bib0680","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nature14432","article-title":"Structural and functional features of central nervous system lymphatic vessels","volume":"523","author":"Louveau","year":"2015","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.biopha.2019.108843_bib0685","doi-asserted-by":"crossref","first-page":"4492","DOI":"10.4049\/jimmunol.1003953","article-title":"MHC-independent genetic factors control the magnitude of CD4+ T cell responses to amyloid-beta peptide in mice through regulatory T cell-mediated inhibition","volume":"187","author":"Toly-Ndour","year":"2011","journal-title":"J. Immunol."},{"key":"10.1016\/j.biopha.2019.108843_bib0690","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.bbi.2016.02.009","article-title":"T-cell brain infiltration and immature antigen-presenting cells in transgenic models of Alzheimer\u2019s disease-like cerebral amyloidosis","volume":"54","author":"Ferretti","year":"2016","journal-title":"Brain Behav. Immun."},{"issue":"1","key":"10.1016\/j.biopha.2019.108843_bib0695","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3233\/JAD-2009-1015","article-title":"Dramatic shifts in circulating CD4 but not CD8 T cell subsets in mild Alzheimer\u2019s disease","volume":"17","author":"Larbi","year":"2009","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.biopha.2019.108843_bib0700","doi-asserted-by":"crossref","first-page":"363310","DOI":"10.1038\/ncomms4633","article-title":"MHC-I expression renders catecholaminergic neurons susceptible to T-cell-mediated degeneration","volume":"5","author":"Cebrian","year":"2014","journal-title":"Nat. Commun."},{"issue":"23","key":"10.1016\/j.biopha.2019.108843_bib0705","doi-asserted-by":"crossref","first-page":"9592","DOI":"10.1523\/JNEUROSCI.5610-12.2013","article-title":"MHCII is required for alpha-synuclein-induced activation of microglia, CD4 T cell proliferation, and dopaminergic neurodegeneration","volume":"33","author":"Harms","year":"2013","journal-title":"J. Neurosci."},{"issue":"7660","key":"10.1016\/j.biopha.2019.108843_bib0710","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/nature22815","article-title":"T cells from patients with Parkinson\u2019s disease recognize alpha-synuclein peptides","volume":"546","author":"Sulzer","year":"2017","journal-title":"Nature"},{"issue":"7111","key":"10.1016\/j.biopha.2019.108843_bib0715","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1038\/nature05133","article-title":"Functional epistasis on a common MHC haplotype associated with multiple sclerosis","volume":"443","author":"Gregersen","year":"2006","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.biopha.2019.108843_bib0720","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.mehy.2015.06.016","article-title":"Common pathophysiology affecting diabetic retinopathy and Parkinson\u2019s disease","volume":"85","author":"Tian","year":"2015","journal-title":"Med. Hypotheses"},{"issue":"7","key":"10.1016\/j.biopha.2019.108843_bib0725","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1001\/jamaneurol.2017.0469","article-title":"Genome-wide pleiotropy between parkinson disease and autoimmune diseases","volume":"74","author":"Witoelar","year":"2017","journal-title":"JAMA Neurol."},{"issue":"11","key":"10.1016\/j.biopha.2019.108843_bib0730","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/nrneurol.2017.140","article-title":"Parkinson disease: Exenatide - a drug for diabetes and Parkinson disease?","volume":"13","author":"Jankovic","year":"2017","journal-title":"Nat. Rev. Neurol."},{"issue":"1","key":"10.1016\/j.biopha.2019.108843_bib0735","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1186\/s13024-018-0245-9","article-title":"Tau oligomers mediate alpha-synuclein toxicity and can be targeted by immunotherapy","volume":"13","author":"Gerson","year":"2018","journal-title":"Mol. Neurodegener."},{"issue":"1","key":"10.1016\/j.biopha.2019.108843_bib0740","doi-asserted-by":"crossref","first-page":"4310","DOI":"10.1186\/s13024-018-0276-2","article-title":"Immunotherapy targeting toll-like receptor 2 alleviates neurodegeneration in models of synucleinopathy by modulating alpha-synuclein transmission and neuroinflammation","volume":"13","author":"Kim","year":"2018","journal-title":"Mol. Neurodegener."},{"issue":"10","key":"10.1016\/j.biopha.2019.108843_bib0745","first-page":"622","article-title":"Xadago (Safinamide): a monoamine oxidase B inhibitor for the adjunct treatment of motor symptoms in parkinson\u2019s disease","volume":"42","author":"Cruz","year":"2017","journal-title":"P T"},{"key":"10.1016\/j.biopha.2019.108843_bib0750","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.2147\/TCRM.S139545","article-title":"Safinamide in the management of patients with Parkinson\u2019s disease not stabilized on levodopa: a review of the current clinical evidence","volume":"14","author":"Bette","year":"2018","journal-title":"Ther. Clin. Risk Manage."},{"issue":"38","key":"10.1016\/j.biopha.2019.108843_bib0755","doi-asserted-by":"crossref","first-page":"60823","DOI":"10.18632\/oncotarget.11661","article-title":"Piperine induces autophagy by enhancing protein phosphotase 2A activity in a rotenone-induced Parkinson\u2019s disease model","volume":"7","author":"Liu","year":"2016","journal-title":"Oncotarget."},{"key":"10.1016\/j.biopha.2019.108843_bib0760","article-title":"Patients\u2019 expectations and satisfaction in subthalamic nucleus deep brain stimulation for Parkinson disease: 6-year follow-up","author":"Lin","year":"2018","journal-title":"World Neurosurg."}],"container-title":["Biomedicine & Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332218377989?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332218377989?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T11:39:01Z","timestamp":1760096341000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332218377989"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":152,"alternative-id":["S0753332218377989"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2019.108843","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Progress of immunotherapy of anti-\u03b1-synuclein in Parkinson\u2019s disease","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2019.108843","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"108843"}}